Author

A. D. Kashuba

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Evolutionary Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:clinical cohort / trial· 1 Assay:DNA methylation· 1 Assay:metabolomics· 1 Organism:non-human primate· 1

Frequent Co-Authors

M. Cottrell· 3 shared B. F. Keele· 2 shared A. F. Feder· 1 shared A. Khoei· 1 shared A. Schauer· 1 shared A. Tropsha· 1 shared B. Policicchio· 1 shared C. Apetrei· 1 shared

Activity by Year

2017-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPharmacology & Toxicology

M. Cottrell

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

HIV Pharmacology Data Repository (PDR): Setting the New Information Sharing Standard for Pharmacokinetic Studies

L. A. R. Tompkins, O. Kapeljushnik, R. Hubal, A. Khoei, J. Dumond, A. D. Kashuba, A. Tropsha, M. L. Cottrell

The paper introduces a standardized framework for sharing pharmacokinetic data and demonstrates its utility through computational modeling of HIV drug concentration vs. time data.

bioRxiv · Feb 13, 2023 · PreprintPharmacology & Toxicology

Validation of an LC-MS/MS Assay for the Simultaneous Determination of Bictegravir, Doravirine, and Raltegravir in Human Plasma

A. Schauer, C. Sykes, M. Cottrell, A. D. Kashuba

The paper validates an LC-MS/MS method to simultaneously measure Bictegravir, Doravirine, and Raltegravir in human plasma across a wide range.

bioRxiv · May 21, 2020Pharmacology & Toxicology

Marginal Effects of Systemic CCR5 Blockade with Maraviroc on Oral Simian Immunodeficiency Virus Transmission to Infant Macaques

E. Brocca-Cofano, C. Xu, K. Wetzel, M. Cottrell, B. Policicchio, K. Raehtz, D. Ma, T. Dunsmore, G. Haret-Richter, K. Musaitif, B. F. Keele, A. D. Kashuba, R. Collman, I. Pandrea, C. Apetrei

This study evaluates the effectiveness of maraviroc in preventing oral SIV transmission to infant macaques, finding only marginal impact despite CCR5 blockade.

bioRxiv · Apr 11, 2018Immunology

High resolution spatio-temporal assessment of simian/human immunodeficiency virus (SHIV) evolution reveals a highly dynamic process within the host

A. F. Feder, C. Kline, P. Polacino, M. Cottrell, A. D. Kashuba, B. F. Keele, S.-L. Hu, D. A. Petrov, P. Pennings, Z. Ambrose

This study tracks SHIV evolution in macaques to show drug resistance spreads rapidly across compartments but does not equilibrate, with the gut showing faster turnover and less wild-type virus retention.

PLOS Pathogens · May 25, 2017Peer-reviewedEvolutionary Biology